Brief: Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
14/05/2024 13:52
May 14 (Reuters) - Fortress Biotech Inc FBIO.O :
* FORTRESS BIOTECH ANNOUNCES FIRST PATIENT DOSED IN
MULTI-CENTER
PHASE 2 STUDY OF TRIPLEX FOR CONTROL OF CMV IN PATIENTS
UNDERGOING LIVER TRANSPLANTATION
Source text for Eikon: ID:nGNX3v2SfV
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi